Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients
Carregando...
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2011
Editora
HINDAWI PUBLISHING CORPORATION
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, p.1-5, 2011
Resumo
Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA). Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use. Total cholesterol (TC) and its fractions, inflammatory markers, and prednisone use were evaluated. Results. The comparisons of lipid levels between baseline and after three months (3M) of anti-TNF therapy showed that there was a significant increase in mean triglycerides (117.8 +/- 49.7 versus 140.1 +/- 64.1 mg/dL, P = 0.028) and VLDL-c (23.6 +/- 10.5 versus 28.4 +/- 13.7 mg/dL, P = 0.019) levels. In contrast, there were no differences in the mean TC (P = 0.28), LDL-c (P = 0.42), and HDL-c (P = 0.26) levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike (P > 0.05). Positive correlations were found between VLDL-c and CRP (r = 0.647, P = 0.009) and between triglycerides and CRP (r = 0.604, P = 0.017) levels at 3M. ESR reduction was observed after 3M (P = 0.04). Mean prednisone dose remained stable at beginning and at 3M (P = 0.37). Conclusion. This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients after three months.
Palavras-chave
Referências
- Kimhi O, 2007, SEMIN ARTHRITIS RHEU, V36, P203, DOI 10.1016/j.semarthrit.2006.09.001
- Kavanaugh A, 2007, ANN RHEUM DIS, V66, P498, DOI 10.1136/ard.2006.058339
- SIEDEL J, 1983, CLIN CHEM, V29, P1075
- Shbeeb M, 2000, J RHEUMATOL, V27, P1247
- Han CL, 2006, J RHEUMATOL, V33, P2167
- Popa C, 2005, ANN RHEUM DIS, V64, P303, DOI 10.1136/ard.2004.023119
- Soubrier M, 2008, JOINT BONE SPINE, V75, P22, DOI 10.1016/j.jbspin.2007.04.014
- Mathieu S, 2010, JOINT BONE SPINE, V77, P50, DOI 10.1016/j.jbspin.2009.05.012
- Tsankov N, 1998, CLIN DERMATOL, V16, P333, DOI 10.1016/S0738-081X(98)00005-4
- Soriano ER, 2006, J RHEUMATOL, V33, P1422
- Skoog T, 2002, EUR HEART J, V23, P376, DOI 10.1053/euhj.2001.2805
- MEMON RA, 1993, ENDOCRINOLOGY, V132, P2246, DOI 10.1210/en.132.5.2246
- Eder L, 2008, J RHEUMATOL, V35, P877
- Seriolo B, 2006, ANN NY ACAD SCI, V1069, P414, DOI 10.1196/annals.1351.039
- BUSKILA D, 1992, J RHEUMATOL, V19, P1115
- LEONARD DG, 1978, MAYO CLIN PROC, V53, P511
- FOSSATI P, 1982, CLIN CHEM, V28, P2077
- Antoniou C, 2007, BRIT J DERMATOL, V156, P1090, DOI 10.1111/j.1365-2133.2007.07835.x
- Popa C, 2007, ANN RHEUM DIS, V66, P1503, DOI 10.1136/ard.2006.066191
- Spanakis E, 2006, J RHEUMATOL, V33, P2440
- Popa C, 2007, J LIPID RES, V48, P751, DOI 10.1194/jlr.R600021-JLR200
- ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.1780361206
- VEALE D, 1993, ARTHRITIS RHEUM, V36, P893, DOI 10.1002/art.1780360705
- Austin MA, 1998, AM J CARDIOL, V81, P7
- ESPINOZA LR, 1992, J RHEUMATOL, V19, P872
- Gonzalez-Juanatey C, 2007, ARTHRIT RHEUM-ARTHR, V57, P1074, DOI 10.1002/art.22884
- Jacobson TA, 2007, CLIN THER, V29, P763, DOI 10.1016/j.clinthera.2007.05.002
- MOLL J M H, 1973, Seminars in Arthritis and Rheumatism, V3, P55, DOI 10.1016/0049-0172(73)90035-8
- ONEILL T, 1994, BAILLIERE CLIN RHEUM, V8, P245, DOI 10.1016/S0950-3579(94)80017-0
- Ridker Paul M., 2003, Cardiology Clinics, V21, P315, DOI 10.1016/S0733-8651(03)00079-1
- Ross R, 1999, NEW ENGL J MED, V340, P115
- SPRIGGS DR, 1988, J NATL CANCER I, V80, P1039, DOI 10.1093/jnci/80.13.1039
- WARNICK GR, 1979, CLIN CHEM, V25, P596